clinical trial · NCT06041776
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Betta Pharmaceuticals Co., Ltd.·phase3·recruiting·n = 570
Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant TherapyBefotertinib + Icotinib placeboIcotinib + Befotertinib placebo
brief summary
This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.
started
Mar 28, 2023
primary completion
Apr 30, 2028
completion
Nov 30, 2029
last updated
Sep 22, 2023
official title
A Multicenter, Randomized, Controlled, Double Blind, Double Simulated, Phase III Clinical Study of Befotertinib vs Icotinib for Postoperative Adjuvant Treatment of IB-IIIB (T3N2M0) Stage Non Small Cell Lung Cancer With Positive EGFR Sensitive Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol